We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-3 of 3

IP challenges for the personalised medicines industry - gene claims (part 1)

  • Barker Brettell LLP
  • -
  • European Union, United Kingdom, USA
  • -
  • May 9 2013

When you go to the doctor you expect to be asked a lot of questions about your symptoms and your lifestyle, as the doctor builds up a clinical

U.K. jumps on “pay-to-delay” bandwagon

  • Fish & Richardson PC
  • -
  • United Kingdom, USA
  • -
  • April 24 2013

The U.K. Office of Fair Trading ("OFT") jumped on the "pay-to-delay" bandwagon last week when it issued a "Statement of Objections," indicating a

UK Supreme Court steps into line with Europe, but rejects U.S. approach

  • McDermott Will & Emery
  • -
  • European Union, United Kingdom, USA
  • -
  • November 30 2011

The UK’s highest court recently considered the provisions of the European Patent Convention (EPC) centering on the “susceptible of industrial application” requirement in the context of a patent describing a DNA sequence for a new protein, Neutrokine-α, which was a member of a group of similar proteins known as the TNF ligand superfamily